Brody, J., Belada, D., Morillo, D., Costello, R., Trneny, M., Vos, S. D., Musuraca, G., Vitolo, U., Lewis, D., Christensen, J., Nijland, M., Jiang, T., Karagoz, K., Steele, A. J., Marek, J., Wang, L., Risum, M., Córdoba, R., Jørgensen, J. (2025). Epcoritamab + GemOx achieves durable >2-year remissions in relapsed/refractory (R/R) 2L+ diffuse large B-cell lymphoma (DLBCL): Long-term data reinforce clinical potential of the regimen across a diverse patient population. Blood. https://doi.org/10.1182/blood-2025-3736